News
COVID-19 Research at UCLA
Innovation and Research keeps going at UCLA. We've put together a list of current COVID-19 research happening at UCLA.
UCLA TDG STAFF WORKING REMOTE
IMPORTANT ANNOUNCEMENT REGARDING
UCLA TECHNOLOGY DEVELOPMENT GROUP
UCLA TDG is exercising caution with regard to novel coronavirus (COVID-19). Accordingly, most of our staff are working remotely. Remote TDG staff will use the Zoom Meeting client to conduct meetings, and are available via phone and email during regular business hours.
UCLA Researchers Currently Developing Rapid COVID-19 Testing
UCLA researchers in the Department of Molecular and Medical Pharmacology have discovered high affinity binding affibodies to COVID-19’s nucleocapsid protein that provide the basis for an ELISA-based diagnostic platform. The researchers are currently developing affibody-coated test strips for saliva detection of COVID-19 in high population settings or at home testing. More information can be found here
Innovation Fund Deadline Extended to April 9th
UCLA Technology Development Group announces an open call for the Innovation Fund
All Therapeutic and Medtech projects will be considered. Funded Projects receive up to $200K
Therapeutic Applications DUE: March 1, 2020
Medtech Applications DEADLINE EXTENDED! April 9, 2020
UCLA TDG Dec 2019 Innovation Magazine
Enjoy the December 2019 Issue of Innovation Magazine
Highlights include TDG's Year End numbers, the latest on AI at UCLA, an open pitch call for the Innovation Fund and TDG's Spring conferences!
In Vivo Feature: How Proximity Creates Partnerships
How Proximity Creates Partnerships
VC Playbook: Sean Harper’s Bet On A Rising City Of Angels
21 Oct 2019 INTERVIEWS
by William Looney @BillInVivo william.looney@informa.com
Executive Summary
Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.
Reprinted with permission from